@JonathanWosen
Pinned post
www.statnews.com Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug. 
www.statnews.com Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent. 
www.statnews.com AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations. 
www.statnews.com Top immunology association divided over $8.4-billion California ballot measure to fund the field,... Internal emails obtained by STAT show that the American Association of Immunologists is sharply divided over California's Proposition 38, even though it would provide $8.4 billion in taxpayer dollars... 